Mizuho cuts Corteva stock price target to $13 on Brazil woes

Mizuho cut Corteva's (CTVA) price target to $13 from $16, citing Brazil market woes and reduced EBITDA guidance. CTVA shares fell 22% last week, trading near a 52-week low. The company's Q3 earnings missed estimates, with a 33% drop in operating EBITDA. RBC and Oppenheimer also lowered targets and ratings, citing execution challenges and Brazil headwinds.

Original reporting
Published Nov 16, 2026, 11:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CTVA
Bearish
high confidence
Mentioned
$CTVA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CTVABearishMed
01

Why it matters

The earnings miss and target cut reflect execution challenges in Brazil, a key market for the company.

02

Market read

Corteva's weak earnings and lowered guidance may trigger a sell‑off, affecting agribusiness and related ETFs.

03

What to watch

Potential recovery if Brazil conditions improve or if cost‑cutting measures take effect.

Relevance 8/10Novelty 7/10Timing: pre-market today

Background

Corteva recently spun off its seed business and is now operating as a standalone crop protection company.

Company-level read

Ticker impact

$CTVABearishHigh confidence
Context

Mizuho cut Corteva's price target to $13 and reported a Q3 earnings miss, triggering a 22% share decline.

Expected impact

likely further downside as investors price in weaker Brazil outlook and lower guidance.

Evidence & confidence

The article provides fresh earnings numbers, a target cut, and guidance reductions, all new information that typically drives price moves.

Market effects

Crop protection sector may face broader pressure from Brazil demand slowdown.

Latin American agribusiness exposure could weigh on related stocks.

Limited to investors with exposure to Corteva and agricultural inputs.

Counterpoint

The 7.64% dividend yield may attract yield‑seeking investors despite short‑term weakness.

Key entities

  • Corteva Inc.

    U.S. crop protection firm (ticker CTVA).

  • Mizuho

    Analyst house that lowered the price target.

Related articles

$CTVAMed

Corteva Q3 Earnings Call Highlights Brazil Woes and Outlook Cut

Corteva (CTVA) reported Q3 2026 adjusted earnings of $0.06/share, missing estimates, and revenues of $1.52B, also below consensus. The company cut its full-year EBITDA outlook to $1.1B-$1.13B due to Brazil's inventory issues, pricing pressure, and volume declines. CEO Luther Kissam and CFO Jeffrey Rudolph highlighted inventory normalization and cost reductions as priorities, with a focus on new products for growth. Full-year earnings are now projected at $0.76-$0.80/share.

$CTVAMedAI 8/10

Corteva Q3 Earnings Call Highlights

Corteva (CTVA) reported Q3 sales of $5.4B, down 1%, with operating EBITDA flat at $943M. Growth in North America, EMEA, and Asia Pacific offset pressure in Brazil, where market sellout was down 12% YTD. CEO Kissam discussed cost-cutting measures, including a hiring freeze and R&D project reviews. The company expects 2027 growth and share repurchases, with $1.8B cash on hand at Q3 end. New products Arylex and Pyraxalt saw over 20% volume growth, with combined annual revenue of $650M.

$CTVAMedAI 8/10

Corteva Inc (CTVA) Q3 2026 Earnings Call Transcript

Corteva Inc. (CTVA) reported Q3 2026 earnings, with net sales at $1.6B, down 9% YoY, and operating EBITDA at $222M, down 17%. Growth was seen in North America, EMEA, and Asia Pacific, but Latin America sales dropped 31% due to market challenges. The company maintained flat EBITDA levels YoY and expanded margins despite $230M in pricing headwinds. Corteva declared its first quarterly dividend and remains on track for a year-end cash position of $1.5B.